Sunday 18 October 2026
Export AVLN’s income statement to Excel — free account
Avalyn Pharma Inc.
AVLN
Insiders bought in the last twelve months.
23.66
0.98
−3.98%
Follow AVLN
| Older periods | Jun '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
Current Ratio |
+1 more quarter Free account |
— | 10.19 | 11.03 | 33.12 |
Net Debt/EBITDA |
0.00 | 0.00 | 3.86 | 10.77 | |
Debt/Assets |
0.00% | 0.00% | 10.92% | 3.48% | |
Debt/Equity |
0.00 | 0.00 | (0.06) | 0.04 | |
Asset Turnover |
— | — | — | 0.00 | |
Operating CF/Net income |
1.03 | — | 1.11 | 0.90 | |
Capex/Depreciation |
0.00 | — | 1.88 | 5.08 | |
Interest Coverage |
— | — | (284.79) | (115.04) | |
Research and Development Expense of Revenue |
0.00% | — | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
0.00% | — | 0.00% | 0.00% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
0.00% | — | 0.00% | 0.00% | |
Free Cash Flow per Share |
(18.07) | — | (24.55) | (0.89) | |
Cash per Share |
0.00 | 0.00 | 100.05 | 11.89 | |
Shareholders Equity per Share |
0.00 | 0.00 | (214.71) | 13.43 | |
Interest Debt per Share |
0.00 | — | 0.00 | 0.00 | |
Book value per Share |
0.00 | 0.00 | (214.71) | 13.43 | |
Free Cash Flow |
(20.70) | — | (30.21) | (26.34) | |
Working Capital |
— | 129.47 | 118.20 | 347.18 | |
Capital Expenditures |
0.00 | — | (0.32) | (0.27) | |
Net Current Asset Value |
0.00 | (243.98) | (269.92) | 330.89 | |
| Other line items | |||||
Quick Ratio |
— | 9.82 | 10.45 | 32.60 | |
Revenue per Share |
0.00 | — | 0.00 | 0.00 | |
Operating CF per Share |
(18.07) | — | (24.29) | (0.88) | |
Capex per Share |
0.00 | — | (0.26) | (0.01) | |
Average Assets |
— | — | — | 212.72 | |
Capex to Sales |
0.00 | — | 0.00 | 0.00 |
Columns are period end dates